Evidence map›Paper›PMID 41909233›Full record

ArticleMaterials today. Bio2026

Degradable STING nanomodulators orchestrate the innate-to-adaptive immune response for NIR-II photothermal-immunotherapy via a cancer-immunity cycle.

Qiaolin Wei, Zirui Zhu, Yue Li, Siying Sun, Ge Gao, Yinghong Wan, Yi Hao, Jiaying Lei, Jiahao Xu, Quan Hu and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Qiaolin WeiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Zirui ZhuZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Yue LiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Siying SunZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Ge GaoZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Yinghong WanZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Yi HaoZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Jiaying LeiZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Jiahao XuZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Quan HuZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Wei ZhengZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Yong GuoZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.
Jia-Wei ShenZhejiang Provincial Key Laboratory of Anti-Cancer Chinese Medicines and Natural Medicines, School of Pharmacy, Hangzhou Normal University, Zhejiang, 311121, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Activating the cyclic GMP-AMP synthase-stimulator of interferon genes (cGAS-STING) pathway has become a valuable approach for enhancing the efficacy of immunotherapeutic treatments. Here, a degradable Au-Zn bimetallic STING nanomodulator (designated as GZn NPs) was constructed to coordinate the second near-infrared window (NIR-II) photothermal therapy and immunotherapy. Under acidic tumor microenvironment conditions, plus with NIR-II laser irradiation, GZn NPs undergo responsive degradation, releasing Zn

Indexed as

Cancer-immunity cyclecGAS-STING pathwayInnate-to-adaptive immune responseNIR-II photothermal immunotherapySTING nanomodulators

Identifiers

PMID41909233
PMCPMC13022635

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.